Cargando…
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471666/ https://www.ncbi.nlm.nih.gov/pubmed/30909387 http://dx.doi.org/10.3390/ijms20061451 |
_version_ | 1783412077789970432 |
---|---|
author | Zajączkowska, Renata Kocot-Kępska, Magdalena Leppert, Wojciech Wrzosek, Anna Mika, Joanna Wordliczek, Jerzy |
author_facet | Zajączkowska, Renata Kocot-Kępska, Magdalena Leppert, Wojciech Wrzosek, Anna Mika, Joanna Wordliczek, Jerzy |
author_sort | Zajączkowska, Renata |
collection | PubMed |
description | Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. There are six main substance groups that cause damage to peripheral sensory, motor and autonomic neurons, which result in the development of CIPN: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). Among them, the most neurotoxic are platinum-based agents, taxanes, ixabepilone and thalidomide; other less neurotoxic but also commonly used drugs are bortezomib and vinca alkaloids. This paper reviews the clinical picture of CIPN and the neurotoxicity mechanisms of the most common antineoplastic agents. A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies. |
format | Online Article Text |
id | pubmed-6471666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64716662019-04-26 Mechanisms of Chemotherapy-Induced Peripheral Neuropathy Zajączkowska, Renata Kocot-Kępska, Magdalena Leppert, Wojciech Wrzosek, Anna Mika, Joanna Wordliczek, Jerzy Int J Mol Sci Review Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. There are six main substance groups that cause damage to peripheral sensory, motor and autonomic neurons, which result in the development of CIPN: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). Among them, the most neurotoxic are platinum-based agents, taxanes, ixabepilone and thalidomide; other less neurotoxic but also commonly used drugs are bortezomib and vinca alkaloids. This paper reviews the clinical picture of CIPN and the neurotoxicity mechanisms of the most common antineoplastic agents. A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies. MDPI 2019-03-22 /pmc/articles/PMC6471666/ /pubmed/30909387 http://dx.doi.org/10.3390/ijms20061451 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zajączkowska, Renata Kocot-Kępska, Magdalena Leppert, Wojciech Wrzosek, Anna Mika, Joanna Wordliczek, Jerzy Mechanisms of Chemotherapy-Induced Peripheral Neuropathy |
title | Mechanisms of Chemotherapy-Induced Peripheral Neuropathy |
title_full | Mechanisms of Chemotherapy-Induced Peripheral Neuropathy |
title_fullStr | Mechanisms of Chemotherapy-Induced Peripheral Neuropathy |
title_full_unstemmed | Mechanisms of Chemotherapy-Induced Peripheral Neuropathy |
title_short | Mechanisms of Chemotherapy-Induced Peripheral Neuropathy |
title_sort | mechanisms of chemotherapy-induced peripheral neuropathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471666/ https://www.ncbi.nlm.nih.gov/pubmed/30909387 http://dx.doi.org/10.3390/ijms20061451 |
work_keys_str_mv | AT zajaczkowskarenata mechanismsofchemotherapyinducedperipheralneuropathy AT kocotkepskamagdalena mechanismsofchemotherapyinducedperipheralneuropathy AT leppertwojciech mechanismsofchemotherapyinducedperipheralneuropathy AT wrzosekanna mechanismsofchemotherapyinducedperipheralneuropathy AT mikajoanna mechanismsofchemotherapyinducedperipheralneuropathy AT wordliczekjerzy mechanismsofchemotherapyinducedperipheralneuropathy |